Combination Lipid Therapy in Type 2 Diabetes
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of triglycerides with the proliferator activated receptor-alpha agonist fenofibrate failed to reduce ASCVD events in 2 separate trials in persons with T2D: (Fenofibrate Intervention and Event Lowering in Diabetes [FIELD]377 and ACCORD-Lipid),367 although the mean baseline triglyceride levels were 153 mg/dL in FIELD377 and 162 mg/dL in ACCORD-Lipid.367”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [377]
In the citing paper
“Yet, subgroup analyses have strongly suggested that patients with high triglyceride and low high-density lipoprotein (HDL) cholesterol levels might derive substantial clinical benefit from decreased triglyceride levels, particularly if they have concomitant type 2 diabetes. 7,8”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [7]
In the citing paper
“the significant reduction of CV event risk was shown for each test, particularly in the post-hoc analysis of the subclasses of patients with or without statin who had atherogenic dyslipidemia (high serum TG and low HDL-C levels) [12].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [12]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Robins, S. J., Collins, D., Wittes, J. T., Papademetriou, V., Deedwania, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., Wexler, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 921
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Research works printed but not linked: 2
- 10.1001/jama.2009.1619 · DOI · Paper page
- 10.1056/NEJMoa1001282 · DOI · Paper page
Cited by
Items 201–244 of 244
Los fibratos en el control del síndrome metabólico
Guijarro, C. (2013) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2013.01.002 · Cited by 1
Raised Blood Cholesterol: Preventable Risk Factor for Cardiovascular Disease
Tokgözoğlu, L. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-22357-5_8 · Cited by 2
Fujioka, Y. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed088 · Cited by 1
Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?
COPPLE, T. M., & Ciffone, N. A. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000526627.04268.80 · Cited by 1
Pedro‐Botet, J., Barrios, V., Sánchez‐Margalet, V., Tamargo, J. L., Arrieta, F., Gámez, J. M., Gimeno-Orna, J. A., Escobar, C., Gómez‐Doblas, J. J., & Pérez, A. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.11.009 · Cited by 2
Genetics of Coronary Artery Disease in Diabetes Mellitus
Morieri, M. L., & Doria, A. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_6 · Cited by 1
Názara-Otero, C., Argüeso, R. M., Pedro‐Botet, J., Pintó, X., Millán, J., Seijo, M. P., Fernández, P. A., Ameneiros, M. E., del Alamo, A., Rodríguez, A., et al. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.07.002 · Cited by 3
Mendoza, C., Quiñones, V., Amigo, L., Busso, D., Alberto Maiz, G., & Rigotti, A. (2016) · Revista chilena de cardiología · doi:10.4067/s0718-85602016000200006 · Cited by 1
Brea, Á., Millán, J., Ascaso, J. F., Blasco, M., Rodríguez, Á. D., Hernández‐Mijares, A., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.04.002 · Cited by 2
Perlstein, T. S., & Krichavsky, M. Z. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00035-7 · Cited by 2
Rasool, S., Siddique, A., & Amin, K. (2016) · Annals of Punjab Medical College · Cited by 1
Heart Failure Burden in Diabetes: Can Fenofibrate Provide Additional Hope?
Morieri, M. L. (2022) · Diabetes Care · doi:10.2337/dci22-0012 · Cited by 3
Klinische Befunde und rationelle Differenzialdiagnostik der diabetischen Dyslipidämie
von Eckardstein, A. (2012) · Der Diabetologe · doi:10.1007/s11428-012-0890-5
Kardiovaskuläres Risiko und medikamentöse Lipidtherapie
Stulnig, T. M. (2012) · Der Diabetologe · doi:10.1007/s11428-012-0891-4
Pandya, H. (2014) · International Journal of Medical Science and Public Health · doi:10.5455/ijmsph.2014.010420142
Review: Fibrates reduce risk for cardiovascular outcomes
Santos, R. D. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-10-201011160-02011
Fibrate Use in the United States and Canada—Reply
Jackevicius, C. A. (2011) · JAMA · doi:10.1001/jama.2011.947
Hypertriglyceridaemia in type 2 diabetes: prevalence, risk and primary care management
Sinclair, A. J. (2012) · The British Journal of Diabetes · doi:10.1177/1474651412442409
Hypertriglyceridemia: Should We Treat?
Brinton, E. A. (2014) · The Endocrine Society eBooks · doi:10.1210/mtp3.9781936704835.ch27
Therapy to Manage Low High-Density Lipoprotein Cholesterol and Elevated Triglycerides
Davidson, M. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00025-4
Diabète de type2 etdyslipidémie
Ziegler, O., & Böhme, P. (2017) · doi:10.1016/b978-2-294-74646-8.00019-5
Affect of late-onset prenatal care on antenatal diagnosis.
Bodurtha, J. N., Corey, L., & Nance, W. E. (1986) · Virginia medical
Review: Long-chain ω-3 fatty acids have no effect on mortality or overall cardiovascular events
Smith, D. A. (2018) · Annals of Internal Medicine · doi:10.7326/acpjc-2018-169-10-050
Smith, D. A. (2018) · Annals of Internal Medicine · doi:10.7326/acpjc-2018-169-10-051
The Role of Liver X Receptors in Reverse Cholesterol Transport and Atherosclerosis
Breevoort, S. R. (2014) · doi:10.18130/v3925p
New Agents for Treatment of Dyslipidemia
Simha, V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch17
Vergès, B. L. (2022) · doi:10.1093/med/9780198870197.003.0282
Parte I. Fibratos en prevención primaria y secundaria
(2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(16)30083-3
Thérapeutique des désordres associés
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00008-7
Parte II. Combinación de estatina más fibrato (libre y fija)
(2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(16)30084-5
Triglyceride-Rich Lipoproteins
Bazarbashi, N., & Miller, M. J. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_12
Precision Medicine for Diabetes and Dyslipidemia
Alexander, E., Cristiano, E., & Miles, J. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_3
Pemafibrate fails to reduce cardiovascular events in diabetes but may benefit the liver
van den Heuvel, R. (2023) · doi:10.55788/67acdd37
Brinton, E. A., & Pulipati, V. P. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_24
Gilyarevskiy, S. R. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-268
Treatment of dyslipidemia in metabolic syndrome
Vrablík, M. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.017
Pedro‐Botet, J., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Martínez‐Montoro, J. I., de Victoria, E. O.-M., Ribalta, J., Sánchez‐Margalet, V., & Pérez, A. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.09.001
Pedro‐Botet, J., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Martínez‐Montoro, J. I., de Victoria, E. O.-M., Ribalta, J., Sánchez‐Margalet, V., & Pérez, A. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.101523 · Cited by 2
Tratamiento de la hipertrigliceridemia para la reducción del riesgo cardiovascular
Guijarro, C. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500816
Treatment of hypertriglyceridemia to reduce cardiovascular risk
Guijarro, C. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500816
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Williams, P. H., Huang, J., Rasmont, P., & An, J. (2016) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.192318
Vergès, B. L. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)48948-8
Metadata
- Authors
- Saely, C. H., Rein, P., & Drexel, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-08-12
- Volume
- 363
- Issue
- 7
- Pages
- 692-695
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1519335354
- Cited by
- 245
- References
- 12
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 9 · 2023: 12 · 2022: 10 · 2021: 6 · 2020: 17 · 2019: 19 · 2018: 17 · 2017: 23 · 2016: 28 · 2015: 20 · 2014: 14 · 2013: 21 · 2012: 17
- FWCI
- 20.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, lipid-lowering therapy, hypertriglyceridemia, dyslipidemia, cardiovascular risk
- MeSH terms
- Hypolipidemic Agents, Coronary Artery Disease, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Humans, Cholesterol, HDL, Male, Fenofibrate, Risk, Triglycerides, Hypertriglyceridemia, Proportional Hazards Models, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.